agilon health (NYSE:AGL) Announces Quarterly Earnings Results

agilon health (NYSE:AGLGet Rating) released its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02), Fidelity Earnings reports. agilon health had a negative net margin of 4.99% and a negative return on equity of 9.79%. During the same period in the previous year, the firm posted ($0.06) EPS. agilon health updated its Q3 2022 guidance to EPS and its FY 2022 guidance to EPS.

agilon health Trading Up 0.3 %

NYSE:AGL traded up $0.07 during mid-day trading on Friday, hitting $25.59. The company had a trading volume of 2,520,622 shares, compared to its average volume of 2,300,585. agilon health has a fifty-two week low of $14.36 and a fifty-two week high of $38.47. The business’s fifty day moving average is $22.87 and its two-hundred day moving average is $21.17. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.67 and a current ratio of 2.67. The firm has a market cap of $10.41 billion, a P/E ratio of -91.39 and a beta of 1.76.

Insider Buying and Selling at agilon health

In other agilon health news, insider Benjamin Shaker sold 50,000 shares of the stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $27.72, for a total value of $1,386,000.00. Following the transaction, the insider now owns 27,132 shares of the company’s stock, valued at $752,099.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Benjamin Shaker sold 50,000 shares of the firm’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $27.72, for a total transaction of $1,386,000.00. Following the sale, the insider now owns 27,132 shares of the company’s stock, valued at $752,099.04. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Michael L. Smith sold 145,874 shares of the firm’s stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $19.53, for a total value of $2,848,919.22. Following the sale, the director now directly owns 4,126 shares in the company, valued at approximately $80,580.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 711,053 shares of company stock valued at $16,617,223. 3.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On agilon health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new stake in agilon health in the 1st quarter valued at approximately $69,000. Bridgefront Capital LLC acquired a new stake in agilon health in the 1st quarter valued at approximately $212,000. MetLife Investment Management LLC acquired a new stake in agilon health in the 1st quarter valued at approximately $262,000. Neuberger Berman Group LLC bought a new position in agilon health in the first quarter valued at approximately $283,000. Finally, Beacon Pointe Advisors LLC grew its stake in agilon health by 59.4% in the first quarter. Beacon Pointe Advisors LLC now owns 14,432 shares of the company’s stock valued at $366,000 after purchasing an additional 5,376 shares in the last quarter. Institutional investors and hedge funds own 96.24% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. BTIG Research assumed coverage on agilon health in a research note on Friday, June 24th. They set a “neutral” rating for the company. TheStreet upgraded agilon health from a “d+” rating to a “c-” rating in a report on Friday, July 15th. Deutsche Bank Aktiengesellschaft decreased their target price on agilon health from $30.00 to $26.00 in a report on Tuesday, May 10th. Truist Financial increased their target price on agilon health from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, July 14th. Finally, Guggenheim decreased their target price on agilon health from $32.00 to $30.00 in a report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $33.50.

agilon health Company Profile

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.

Featured Articles

Earnings History for agilon health (NYSE:AGL)

Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.